MicroStockHub
Geron Corporation (GERN) lost more than 20% on Wednesday after the cancer drugmaker announced plans to discontinue a late-stage trial for its lead asset imetelstat, marketed as Rytelo, following concerns over its efficacy.
The company said it decided to halt
